How to appeal a Humana genetic testing denial
42 CFR Part 422 Subpart M (Medicare Advantage) · 60-day window · 30-day decision
To appeal a Humana genetic testing denial, file an internal appeal within 60 days of the date on the denial letter through Humana's member or provider portal, under 42 CFR Part 422 Subpart M (Medicare Advantage). Humana returns standard decisions in 30 days; if it upholds the denial you can request an independent external review within 4 months.
The framework that applies to your appeal
Medicare Advantage plans follow a separate appeal track from commercial plans. Reconsideration must be requested within 60 days; if the plan misses its deadline, the case auto-forwards to the IRE (Maximus).
Humana-specific note: Heavily Medicare Advantage focused. MA-specific appeal track (42 CFR Part 422 Subpart M) applies — 60 days to request reconsideration, NOT the 180 days for commercial plans. Auto-forward to IRE (Maximus) if Humana misses deadline.
What Humana's policy requires for genetic testing
Cited policy: Humana Genetic Testing (eviCore for commercial + MA); MA follows CMS NCDs/LCDs
MA must follow CMS NCDs/LCDs. NCD 90.2 for NGS in advanced cancer is the floor.
How Humana denies genetic testing — and how to counter it
Where Humana pushes back: 1) 'eviCore prior auth not obtained'; 2) 'Pharmacogenomic panel testing experimental; only specific drug-gene pairs covered'; 3) 'Carrier screening — only ACOG ethnicity-based / CF/SMA covered'.
Counter-arguments that hold up: For MA: cite NCD 90.2 verbatim — advanced cancer + FDA-approved CDx = national coverage; plan cannot be more restrictive than NCD. For NCD 90.1 / MolDX PGx LCDs: cite specific CPIC level A drug-gene pair. ACOG #691 endorses pan-ethnic ECS.
What Humana typically denies for genetic testing
Across Humana's commercial and Medicare books, denials cluster around a small number of patterns. For genetic testing, expect:
- MA plan step therapy on Part B drugs
- Skilled nursing facility days
- Prior auth on specialty drugs
- OON emergency reduction
Treatments most often denied in this category
These are the genetic testing treatments most often flagged for prior auth, step therapy, or medical necessity review:
- Hereditary cancer panel
- BRCA1/2
- Lynch panel
- Cardiogenetic
- WES / WGS
- Carrier screening
How to submit the appeal to Humana
- Read the denial letter — note the exact denial reason code and the appeal deadline (60 days from the date on the letter).
- Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Humana cited in the denial.
- File the appeal through Humana's portal (members: https://www.humana.com ; providers: https://www.humana.com/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
- If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In KY, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.
Clinician or prior-auth team handling this on the practice side? See Humana's prior-authorization criteria by drug: Humana PA criteria on ApprovalHelp.
Frequently asked questions
How long do I have to appeal a Humana genetic testing denial?
Humana allows 60 days from the date on the denial letter to file an internal appeal. Standard decisions come back within 30 days; expedited decisions for urgent care typically within 72 hours.
What's the fastest way to submit a Humana appeal?
Members can submit through the Humana member portal at https://www.humana.com. Providers should use the provider portal at https://www.humana.com/provider. Faxed and mailed appeals are accepted but take longer.
What denials does Humana most often issue for genetic testing?
For genetic testing, Humana most often denies on: 1) 'eviCore prior auth not obtained'; 2) 'Pharmacogenomic panel testing experimental; only specific drug-gene pairs covered'; 3) 'Carrier screening — only ACOG ethnicity-based / CF/SMA covered'. The strongest counters: For MA: cite NCD 90.2 verbatim — advanced cancer + FDA-approved CDx = national coverage; plan cannot be more restrictive than NCD. For NCD 90.1 / MolDX PGx LCDs: cite specific CPIC level A drug-gene pair. ACOG #691 endorses pan-ethnic ECS.
What if Humana denies the appeal too?
After an internal appeal denial you have the right to an external review by an independent reviewer (IRO) — request it within 4 months of the final internal denial.
Related appeal guides
Start your Genetic testing appeal
Upload your Humana denial letter — DenialHelp drafts a physician-ready appeal in five minutes, aligned to 42 CFR Part 422 Subpart M (Medicare Advantage).
Get started →Contact: hello@denialhelp.com